[go: up one dir, main page]

US20020015950A1 - Atherosclerosis-associated genes - Google Patents

Atherosclerosis-associated genes Download PDF

Info

Publication number
US20020015950A1
US20020015950A1 US09/349,015 US34901599A US2002015950A1 US 20020015950 A1 US20020015950 A1 US 20020015950A1 US 34901599 A US34901599 A US 34901599A US 2002015950 A1 US2002015950 A1 US 2002015950A1
Authority
US
United States
Prior art keywords
seq
polypeptide
polynucleotide
ligand
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/349,015
Other languages
English (en)
Inventor
Karen Anne Jones
Wayne Volkmuth
Michael G. Walker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US09/349,015 priority Critical patent/US20020015950A1/en
Assigned to INCYTE PHARMACEUTICALS, INC. reassignment INCYTE PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: JONES, KAREN ANN, VOLKMUTH, WAYNE, WALKER, MICHAEL G.
Priority to PCT/US2000/017887 priority patent/WO2001004264A2/fr
Priority to JP2001509468A priority patent/JP2003504044A/ja
Priority to CA002378985A priority patent/CA2378985A1/fr
Priority to EP00944981A priority patent/EP1196564A2/fr
Priority to AU58988/00A priority patent/AU5898800A/en
Priority to US09/642,703 priority patent/US6524799B1/en
Publication of US20020015950A1 publication Critical patent/US20020015950A1/en
Priority to US10/219,664 priority patent/US20030129176A1/en
Priority to US10/247,451 priority patent/US20040018188A9/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the invention relates to 34 atherosclerosis-associated polynucleotides identified by their co-expression with known atherosclerosis genes and their corresponding gene products.
  • the invention also relates to the use of these biomolecules in diagnosis, prognosis, prevention, treatment, and evaluation of therapies for diseases associated with atherosclerosis.
  • Atherosclerosis is a disorder characterized by cellular changes in the arterial intima and the formation of arterial plaques containing intra- and extracellular deposits of lipids.
  • the resultant thickening of artery walls and the narrowing of the arterial lumen is the underlying pathologic condition in most cases of coronary artery disease, aortic aneurysm, peripheral vascular disease, and stroke.
  • a cascade of molecules is involved in the cellular morphogenesis, proliferation, and cellular migration which results in an atherosclerotic lesion (Libby et al. (1997) Int. J. Cardiol. 62 (S2): 23-29).
  • a healthy artery consists of three layers.
  • the vascular intima lined by a monolayer of endothelial cells in contact with the blood, contains smooth muscle cells in extracellular matrix.
  • An internal elastic lamina forms the border between the intima and the tunica media.
  • the media contains layers of smooth muscle cells surrounded by a collagen and elastin-rich extracellular matrix.
  • An external elastic lamina forms the border between the media and the adventitia.
  • the adventitia contains nerves and some mast cells and is the origin of the vasa vasorum which supplies blood to the outer layers of the tunica media.
  • Initiation of an atherosclerotic lesion often occurs following vascular endothelial cell injury as a result of hypertension, diabetes mellitus, hyperlipidemia, fluctuating shear stress, smoking, or transplant rejection.
  • the injury results in the local release of nitric oxide and superoxide anions which react to form cytodestructive peroxynitrite radicals, causing injury to the endothelium and myocytes of the intima.
  • This cellular injury leads to the expression of a variety of molecules that produce local and systemic effects.
  • the initial cellular response to injury includes the release of mediators of inflammation such as cytokines, complement components, prostaglandins, and downstream transcription factors.
  • These molecules promote monocyte infiltration of the vascular intima and lead to the upregulation of adhesion molecules which encourage attachment of the monocytes to the damaged endothelial cells. Additionally, components of the extracellular matrix including collagens, fibrinogens, and matrix Gla protein are induced and provide sites for monocyte attachment. Annexins, plasminogen activator inhibitor 1, and nitric oxide synthases are triggered to counteract these effects.
  • Monocytes that infiltrate the lesion accumulate modified low density lipoprotein lipid through scavenger receptors such as CD36 and macrophage scavenger receptor type I.
  • modified lipids is a factor in atherogenesis and is influenced by modifying enzymes such as lipoprotein lipase, carboxyl ester lipase, serum amyloid P component, LDL-receptor related protein, microsomal triglyceride transfer protein, and serum esterases such as paraoxonase.
  • Lipid metabolism is governed by cholesterol biosynthesis enzymes such as 3-hydroxy-3-methylglutaryl coenzyme A synthase, and products of the apolipoprotein genes. Modified lipid stabilization and accumulation is aided by perilipin and alpha-2-macroglobulin.
  • monocytes As monocytes accumulate in the lesion, they can rupture and release free cholesterol, cytokines, and procoagulants into the surrounding environment. This process leads to the development of a plaque which consists of a mass of lipid-engorged monocytes and a lipid-rich necrotic core covered by a fibrous cap. The gradual progression of plaque growth is punctuated by thrombus formation which leads to clinical symptoms such as unstable angina, myocardial infarction, or stroke. Thrombus formation is initiated by episodic plaque rupture which exposes flowing blood to tissue factors, which induce coagulation, and collagen, which activates platelets.
  • cytoskeletal proteins such as calponin, myosin, desmin, and other gene products in the cells.
  • smooth muscle cells lose their contractility and become able to migrate from the media to the intima, to proliferate, and to secrete extracellular matrix components which contribute to arterial intimal thickening.
  • the present invention satisfies a need in the art by providing new compositions that are useful for diagnosis, prognosis, treatment, prevention, and evaluation of therapies for diseases associated with atherosclerosis.
  • the invention provides for a substantially purified polynucleotide comprising a gene that is coexpressed with one or more known atherosclerosis-associated genes in a biological sample.
  • known atherosclerosis-associated genes include and encode human 22 kDa smooth muscle protein, calponin, desmin, smooth muscle myosin heavy chain, alpha tropomyosin, human tissue inhibitor of metalloproteinase 3, human tissue inhibitor of metalloproteinase-2, human tissue inhibitor of metalloproteinase-4, pro alpha 1(I) collagen, collagen alpha-2 type I, collagen alpha-6 type I, procollagen alpha 2(V), collagen VI alpha-2, type VI collagen alpha3, pro-alpha-1 type 3 collagen, pro-alpha-1 (V) collagen, collagenase type IV/matrix metalloproteinase 9/gelatinase B, matrix Gla protein, cathepsin K, fibrinogen beta chain gene, fibrinogen gamma chain gene, pre-pro-
  • the invention also provides a substantially purified polynucleotide comprising a gene that is coexpressed with one or more known atherosclerosis-associated genes in a plurality of samples.
  • the polynucleotide comprises a polynucleotide sequence selected from (a) a polynucleotide encoding a peptide selected from SEQ ID NOs: 1-34; (b) a polynucleotide sequence complementary to the polynucleotide sequence of (a) or (b); and (c) a probe comprising at least 18 sequential nucleotides of the polynucleotide sequence of (a) or (b).
  • the invention further provides a pharmaceutical composition comprising a polynucleotide and a pharmaceutical carrier.
  • the invention additionally provides methods for using a polynucleotide.
  • One method uses the polynucleotide to screen a library of molecules or compounds to identify at least one ligand which specifically binds the polynucleotide and comprises combining the polynucleotide with a library of molecules or compounds under conditions to allow specific binding and detecting specific binding, thereby identifying a ligand which specifically binds the polynucleotide.
  • the library is selected from DNA molecules, RNA molecules, PNAs, mimetics, and proteins; and the ligand identified using the method may be used to modulate the activity of the polynucleotide.
  • a second method uses the polynucleotide to purify a ligand which specifically binds the polynucleotide and comprises combining the polynucleotide with a sample under conditions to allow specific binding, detecting specific binding between the polynucleotide and a ligand, recovering the bound polynucleotide, and separating the polynucleotide from the ligand, thereby obtaining purified ligand.
  • a third method uses the polynucleotide to diagnose a disease or condition associated with the altered expression of a gene that is coexpressed with one or more known atherosclerosis-associated genes in a plurality of biological samples and comprises hybridizing a polynucleotide to a sample under conditions to form one or more hybridization complexes, detecting the hybridization complexes, and comparing the levels of the hybridization complexes with the level of hybridization complexes in a non-diseased sample, wherein the altered level of hybridization complexes compared with the level of hybridization complexes of a non-diseased sample indicates the presence of the disease or condition.
  • a fourth method uses the polynucleotide to produce a polypeptide and comprises culturing a host cell containing an expression vector containing the polynucleotide under conditions for expression of the polypeptide and recovering the polypeptide from cell culture.
  • the invention provides a substantially purified polypeptide comprising the product of a gene that is coexpressed with one or more known atherosclerosis-associated genes in a plurality of samples.
  • the invention also provides a polypeptide comprising a polypeptide sequence selected from (a) the polypeptides encoded by SEQ ID NOs: 1-34; and b) an oligopeptide sequence comprising at least 6 sequential amino acids of the polypeptide sequence of a).
  • The further provides a polypeptide comprising the amino acid sequence of SEQ ID NO: 35.
  • the invention still further provides a pharmaceutical composition comprising a polypeptide and a pharmaceutical carrier.
  • the invention additionally provides methods for using a polypeptide.
  • One method uses the polypeptide to screen a library of molecules or compounds to identify at least one ligand which specifically binds the polypeptide and comprises combining the polypeptide with the library of molecules or compounds under conditions to allow specific binding and detecting specific binding between the polypeptide and ligand, thereby identifying a ligand which specifically binds the polypeptide.
  • the library is selected from DNA molecules, RNA molecules, PNAs, mimetics, polypeptides, agonists, antagonists, and antibodies; and the ligand identified using the method is used to modulate the activity of the polypeptide.
  • a second method uses the polypeptide to purify a ligand from a sample and comprises combining the polypeptide with a sample under conditions to allow specific binding, detecting specific binding between the polypeptide and a ligand, recovering the bound polypeptide, and separating the polypeptide from the ligand, thereby obtaining purified ligand.
  • a third method uses the polypeptide to treat or to prevent a disease associated with the altered expression of a gene that is coexpressed with one or more known atherosclerosis-associated genes in a subject in need and comprises administering to the subject in need the pharmaceutical composition containing the polypeptide in an amount effective for treating or preventing the disease.
  • the invention provides an antibody or Fab comprising an antigen binding site, wherein the antigen binding site specifically binds to the polypeptide.
  • the invention also provides a method for treating or preventing a disease associated with the altered expression of a gene that is coexpressed with one or more known atherosclerosis-associated genes in a subject in need, the method comprising the step of administering to the subject in need the antibody or the Fab in an amount effective for treating or preventing the disease.
  • the invention further provides an immunoconjugate comprising the antigen binding site of the antibody or Fab joined to a therapeutic agent.
  • the invention additionally provides a method for treating or preventing a disease associated with the altered expression of a gene that is coexpressed with one or more known atherosclerosis-associated genes in a subject in need, the method comprising the step of administering to the subject in need the immunoconjugate in an amount effective for treating or preventing the disease.
  • Sequence Listing provides exemplary atherosclerosis-associated gene sequences including polynucleotide sequences SEQ ID NOs: 1-34 and the polypeptide sequence, SEQ ID NO:35. Each sequence is identified by a sequence identification number (SEQ ID NO).
  • Atherosclerosis-associated gene refers to a gene or polynucleotide that exhibits a statistically significant coexpression pattern with known atherosclerosis-associated genes which are useful in the diagnosis, treatment, prognosis, or prevention of atherosclerosis.
  • known atherosclerosis-associated gene refers to a sequence which has been previously identified as useful in the diagnosis, treatment, prognosis, or prevention of atherosclerosis and includes polynucleotides encoding human 22 kDa smooth muscle protein, calponin, desmin, smooth muscle myosin heavy chain, alpha tropomyosin, human tissue inhibitor of metalloproteinase 3, human tissue inhibitor of metalloproteinase-2, human tissue inhibitor of metalloproteinase-4, pro alpha 1(I) collagen, collagen alpha-2 type I, collagen alpha-6 type I, procollagen alpha 2(V), collagen VI alpha-2, type VI collagen alpha3, pro-alpha-1 type 3 collagen, pro-alpha-1(V) collagen, collagenase type IV/matrix metalloproteinase 9/gelatinase B, matrix Gla protein, cathepsin K, fibrinogen beta chain gene, fibrinogen gamma chain gene, pre-pro-von Wille
  • Ligand refers to any molecule, agent, or compound which will bind specifically to a complementary site on a polynucleotide or polypeptide. Such ligands stabilize or modulate the activity of polynucleotides or polypeptides of the invention.
  • ligands are libraries of inorganic and organic molecules or compounds such as nucleic acids, proteins, peptides, carbohydrates, fats, and lipids.
  • NSEQ refers generally to a polynucleotide sequence of the present invention, including SEQ ID NO: 1-34.
  • PSEQ refers generally to a polypeptide sequence of the present invention, including SEQ ID NO:35.
  • a “fragment” refers to a nucleic acid sequence that is preferably at least 20 nucleotides in length, more preferably 40 nucleotides, and most preferably 60 nucleotides in length, and encompasses, for example, fragments consisting of 1-50, 51-400, 401-4000, 4001-12,000 nucleotides, and the like, of SEQ ID NO: 1-34.
  • Gene refers to the partial or complete coding sequence of a gene including 5′ or 3′ untranslated regions.
  • the gene may be in a sense or antisense (complementary) orientation.
  • Polynucleotide refers to a nucleic acid, nucleic acid sequence, oligonucleotide, nucleotide, or any fragment thereof. It may be DNA or RNA of genomic or synthetic origin, double-stranded or single-stranded, and combined with carbohydrate, lipids, protein or other materials to perform a particular activity or form a useful composition. “Oligonucleotide” is substantially equivalent to the terms amplimer, primer, oligomer, element, and probe.
  • Polypeptide refers to an amino acid, amino acid sequence, oligopeptide, peptide, or protein or portions thereof whether naturally occurring or synthetic.
  • a “portion” refers to peptide sequence which is preferably at least 5 to about 15 amino acids in length, most preferably at least 10 amino acids long, and which retains some biological or immunological activity of, for example, a portion of SEQ ID NO: 35.
  • sample is used in its broadest sense.
  • a sample containing nucleic acids may comprise a bodily fluid; an extract from a cell, chromosome, organelle, or membrane isolated from a cell; genomic DNA, RNA, or cDNA in solution or bound to a substrate; a cell; a tissue; a tissue print; and the like.
  • substantially purified refers to a nucleic acid or an amino acid sequence that is removed from its natural environment and that is isolated or separated, and is at least about 60% free, preferably about 75% free, and most preferably about 90% free, from other components with which it is naturally present.
  • Substrate refers to any rigid or semi-rigid support to which polynucleotides or polypeptides are bound and includes membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, capillaries or other tubing, plates, polymers, and microparticles with a variety of surface forms including wells, trenches, pins, channels and pores.
  • a “variant” refers to a polynucleotide or polypeptide whose sequence diverges from SEQ ID NO: 1-35. Polynucleotide sequence divergence may result from mutational changes such as deletions, additions, and substitutions of one or more nucleotides; it may also be introduced to accommodate differences in codon usage. Each of these types of changes may occur alone, or in combination, one or more times in a given sequence.
  • the present invention encompasses a method for identifying biomolecules that are associated with a specific disease, regulatory pathway, subcellular compartment, cell type, tissue type, or species.
  • the method identifies polynucleotides useful in diagnosis, prognosis, treatment, prevention, and evaluation of therapies for diseases associated with atherosclerosis including, but not limited to, stroke, myocardial infarction, hypertension, transient cerebral ischemia, mesenteric ischemia, coronary artery disease, angina pectoris, peripheral vascular disease, intermittent claudication, renal artery stenosis, and hypertension.
  • the method entails first identifying polynucleotides that are expressed in a plurality of cDNA libraries.
  • the identified polynucleotides include genes of known or unknown function which are expressed in a specific disease process, subcellular compartment, cell type, tissue type, or species.
  • the expression patterns of the genes with known function are compared with those of genes with unknown function to determine whether a specified coexpression probability threshold is met. Through this comparison, a subset of the polynucleotides having a high coexpression probability with the known genes can be identified.
  • the high coexpression probability correlates with a particular coexpression probability threshold which is preferably less than 0.001 and more preferably less than 0.00001.
  • the polynucleotides originate from cDNA libraries derived from a variety of sources including, but not limited to, eukaryotes such as human, mouse, rat, dog, monkey, plant, and yeast; prokaryotes such as bacteria; and viruses. These polynucleotides can also be selected from a variety of sequence types including, but not limited to, expressed sequence tags (ESTs), assembled polynucleotide sequences, full length gene coding regions, promoters, introns, enhancers, 5′ untranslated regions, and 3′ untranslated regions. To have statistically significant analytical results, the polynucleotides need to be expressed in at least three cDNA libraries.
  • ESTs expressed sequence tags
  • the cDNA libraries used in the coexpression analysis of the present invention can be obtained from adrenal gland, biliary tract, bladder, blood cells, blood vessels, bone marrow, brain, bronchus, cartilage, chromaffin system, colon, connective tissue, cultured cells, embryonic stem cells, endocrine glands, epithelium, esophagus, fetus, ganglia, heart, hypothalamus, immune system, intestine, islets of Langerhans, kidney, larynx, liver, lung, lymph, muscles, neurons, ovary, pancreas, penis, peripheral nervous system, phagocytes, pituitary, placenta, pleurus, prostate, salivary glands, seminal vesicles, skeleton, spleen, stomach, testis, thymus, tongue, ureter, uterus, and the like.
  • the number of cDNA libraries selected can range from as few as 3 to greater than 10,000.
  • genes are assembled from related sequences, such as assembled sequence fragments derived from a single transcript. Assembly of the sequences can be performed using sequences of various types including, but not limited to, ESTs, extensions, or shotgun sequences.
  • the polynucleotide sequences are derived from human sequences that have been assembled using the algorithm disclosed in “Database and System for Storing, Comparing and Displaying Related Biomolecular Sequence Information”, Lincoln et al. Serial No: 60/079,469, filed Mar. 26, 1998, incorporated herein by reference.
  • differential expression of the polynucleotides can be evaluated by methods including, but not limited to, differential display by spatial immobilization or by gel electrophoresis, genome mismatch scanning, representational difference analysis, and transcript imaging. Additionally, differential expression can be assessed by microarray technology. These methods may be used alone or in combination.
  • Known atherosclerosis-associated genes are selected based on the use of these genes as diagnostic or prognostic markers or as therapeutic targets.
  • the procedure for identifying novel genes that exhibit a statistically significant coexpression pattern with known atherosclerosis-associated genes is as follows. First, the presence or absence of a gene in a cDNA library is defined: a gene is present in a cDNA library when at least one cDNA fragment corresponding to that gene is detected in a cDNA sample taken from the library, and a gene is absent from a library when no corresponding cDNA fragment is detected in the sample.
  • the significance of gene coexpression is evaluated using a probability method to measure a due-to-chance probability of the coexpression.
  • the probability method can be the Fisher exact test, the chi-squared test, or the kappa test. These tests and examples of their applications are well known in the art and can be found in standard statistics texts (Agresti (1990) Categorical Data Analysis, John Wiley & Sons, New York N.Y.; Rice (1988) Mathematical Statistics and Data Analysis, Duxbury Press, Pacific Grove Calif.).
  • a Bonferroni correction (Rice, supra, p. 384) can also be applied in combination with one of the probability methods for correcting statistical results of one gene versus multiple other genes.
  • the due-to-chance probability is measured by a Fisher exact test, and the threshold of the due-to-chance probability is set preferably to less than 0.001, more preferably to less than 0.00001.
  • occurrence data vectors can be generated as illustrated in Table 1. The presence of a gene occurring at least once in a library is indicated by a one, and its absence from the library, by a zero. TABLE 1 Occurrence data for genes A and B Library 1 Library 2 Library 3 . . . Library N gene A 1 1 0 . . . 0 gene B 1 0 1 . . . 0
  • Table 2 presents co-occurrence data for gene A and gene B in a total of 30 libraries. Both gene A and gene B occur 10 times in the libraries. Table 2 summarizes and presents: 1) the number of times gene A and B are both present in a library; 2) the number of times gene A and B are both absent in a library; 3) the number of times gene A is present, and gene B is absent; and 4) the number of times gene B is present, and gene A is absent.
  • the upper left entry is the number of times the two genes co-occur in a library, and the middle right entry is the number of times neither gene occurs in a library.
  • the off diagonal entries are the number of times one gene occurs, and the other does not. Both A and B are present eight times and absent 18 times.
  • Gene A is present, and gene B is absent, two times; and gene B is present, and gene A is absent, two times.
  • the probability (“p-value”) that the above association occurs due to chance as calculated using a Fisher exact test is 0.0003. Associations are generally considered significant if a p-value is less than 0.01 (Agresti, supra; Rice, supra).
  • This method of estimating the probability for coexpression of two genes makes several assumptions. The method assumes that the libraries are independent and are identically sampled. However, in practical situations, the selected cDNA libraries are not entirely independent, because more than one library may be obtained from a single subject or tissue. Nor are they entirely identically sampled, because different numbers of cDNAs may be sequenced from each library. The number of cDNAs sequenced typically ranges from 5,000 to 10,000 cDNAs per library. In addition, because a Fisher exact coexpression probability is calculated for each gene versus 45,233 other assembled genes, a Bonferroni correction for multiple statistical tests is used.
  • the present invention identifies 34 novel atherosclerosis-associated polynucleotides that exhibit strong association with genes known to be specific to atherosclerosis.
  • the results presented in Table 4 show that the expression of the 34 novel atherosclerosis-associated polynucleotides has direct or indirect association with the expression of known atherosclerosis-associated genes. Therefore, the novel atherosclerosis-associated polynucleotides can potentially be used in diagnosis, treatment, prognosis, or prevention of diseases associated with atherosclerosis or in the evaluation of therapies for atherosclerosis. Further, the gene products of the 34 novel atherosclerosis-associated polynucleotides are either potential therapeutics or targets of therapeutics against atherosclerosis.
  • the present invention encompasses a polynucleotide sequence comprising the sequence of SEQ ID NO: 1-34. These 34 polynucleotides are shown by the method of the present invention to have strong coexpression association with known atherosclerosis-associated genes and with each other.
  • the invention also encompasses a variant of the polynucleotide sequence, its complement, or 18 consecutive nucleotides of a sequence provided in the above described sequences.
  • Variant polynucleotide sequences typically have at least about 75%, more preferably at least about 85%, and most preferably at least about 95% polynucleotide sequence identity to NSEQ.
  • NSEQ or the encoded PSEQ may be used to search against the GenBank primate (pri), rodent (rod), mammalian (mam), vertebrate (vrtp), and eukaryote (eukp) databases, SwissProt, BLOCKS (Bairoch et al. (1997) Nucleic Acids Res. 25:217-221), PFAM, and other databases that contain previously identified and annotated motifs, sequences, and gene functions. Methods that search for primary sequence patterns with secondary structure gap penalties (Smith et al. (1992) Protein Engineering 5:35-51) as well as algorithms such as Basic Local Alignment Search Tool (BLAST; Altschul (1993) J. Mol. Evol.
  • polynucleotide sequences that are capable of hybridizing to SEQ ID NO: 1-34, and fragments thereof under stringent conditions.
  • Stringent conditions can be defined by salt concentration, temperature, and other chemicals and conditions well known in the art. Conditions can be selected, for example, by varying the concentrations of salt in the prehybridization, hybridization, and wash solutions or by varying the hybridization and wash temperatures. With some substrates, the temperature can be decreased by adding formamide to the prehybridization and hybridization solutions.
  • Hybridization can be performed at low stringency, with buffers such as 5xSSC with 1% sodium dodecyl sulfate (SDS) at 60° C., which permits complex formation between two nucleic acid sequences that contain some mismatches. Subsequent washes are performed at higher stringency with buffers such as 0.2xSSC with 0.1% SDS at either 45° C. (medium stringency) or 68° C. (high stringency), to maintain hybridization of only those complexes that contain completely complementary sequences. Background signals can be reduced by the use of detergents such as SDS, Sarcosyl, or Triton X-100, and/or a blocking agent, such as salmon sperm DNA.
  • SDS sodium dodecyl sulfate
  • NSEQ can be extended utilizing a partial nucleotide sequence and employing various PCR-based methods known in the art to detect upstream sequences such as promoters and other regulatory elements.
  • PCR-based methods known in the art to detect upstream sequences such as promoters and other regulatory elements.
  • upstream sequences such as promoters and other regulatory elements.
  • Dieffenbach and Dveksler (1995) PCR Primer, a Laboratory Manual, Cold Spring Harbor Press, Plainview N.Y. See, e.g., Dieffenbach and Dveksler (1995) PCR Primer, a Laboratory Manual, Cold Spring Harbor Press, Plainview N.Y.). Additionally, one may use an XL-PCR kit (PE Biosystems, Foster City Calif.), nested primers, and commercially available cDNA libraries (Life Technologies, Rockville Md.) or genomic libraries (Clontech, Palo Alto Calif.) to extend the sequence.
  • primers may be designed using commercially available software, such as OLIGO 4.06 Primer Analysis software (National Biosciences, Plymouth Minn.) or another program, to be about 18 to 30 nucleotides in length, to have a GC content of about 50%, and to form a hybridization complex at temperatures of about 68° C. to 72° C.
  • commercially available software such as OLIGO 4.06 Primer Analysis software (National Biosciences, Madison Minn.) or another program, to be about 18 to 30 nucleotides in length, to have a GC content of about 50%, and to form a hybridization complex at temperatures of about 68° C. to 72° C.
  • NSEQ can be cloned in recombinant DNA molecules that direct the expression of PSEQ, or structural or functional portions thereof, in host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced and used to express the polypeptide encoded by NSEQ.
  • the nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter the nucleotide sequences for a variety of purposes including, but not limited to, modification of the cloning, processing, and/or expression of the gene product.
  • DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences.
  • oligonucleotide-mediated site-directed mutagenesis may be used to introduce mutations that create new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, and so forth.
  • NSEQ may be inserted into an expression vector, i.e., a vector which contains the elements for transcriptional and translational control of the inserted coding sequence in a particular host.
  • elements include regulatory sequences, such as enhancers, constitutive and inducible promoters, and 5′ and 3′ untranslated regions.
  • Methods which are well known to those skilled in the art may be used to construct such expression vectors. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. (See, e.g., Sambrook, supra; and Ausubel, supra).
  • NSEQ A variety of expression vector/host cell systems may be utilized to express NSEQ. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with baculovirus vectors; plant cell systems transformed with viral or bacterial expression vectors; or animal cell systems. For long term production of recombinant proteins in mammalian systems, stable expression in cell lines is preferred.
  • NSEQ can be transformed into cell lines using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable or visible marker gene on the same or on a separate vector. The invention is not to be limited by the vector or host cell employed.
  • host cells that contain NSEQ and that express PSEQ may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations, PCR amplification, and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or amino acid sequences. Immunological methods for detecting and measuring the expression of PSEQ using either specific polyclonal or monoclonal antibodies are known in the art. Examples of such techniques include enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), and fluorescence activated cell sorting (FACS).
  • ELISAs enzyme-linked immunosorbent assays
  • RIAs radioimmunoassays
  • FACS fluorescence activated cell sorting
  • Host cells transformed with NSEQ may be cultured under conditions for the expression and recovery of the polypeptide from cell culture.
  • the polypeptide produced by a transgenic cell may be secreted or retained intracellularly depending on the sequence and/or the vector used.
  • expression vectors containing NSEQ may be designed to contain signal sequences which direct secretion of the polypeptide through a prokaryotic or eukaryotic cell membrane.
  • a host cell strain may be chosen for its ability to modulate expression of the inserted sequences or to process the expressed polypeptide in the desired fashion.
  • modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation.
  • Post-translational processing which cleaves a “prepro” form of the polypeptide may also be used to specify protein targeting, folding, and/or activity.
  • Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities (e.g., CHO, HeLa, MDCK, HEK293, and WI38) are available from the American Type Culture Collection (ATCC, Bethesda Md.) and may be chosen to ensure the correct modification and processing of the expressed polypeptide.
  • ATCC American Type Culture Collection
  • natural, modified, or recombinant nucleic acid sequences are ligated to a heterologous sequence resulting in translation of a fusion polypeptide containing heterologous polypeptide moieties in any of the aforementioned host systems.
  • heterologous polypeptide moieties facilitate purification of fusion polypeptides using commercially available affinity matrices.
  • moieties include, but are not limited to, glutathione S-transferase, maltose binding protein, thioredoxin, calmodulin binding peptide, 6-His, FLAG, c-myc, hemaglutinin, and monoclonal antibody epitopes.
  • nucleic acid sequences are synthesized, in whole or in part, using chemical or enzymatic methods well known in the art (Caruthers et al. (1980) Nucl. Acids Res. Symp. Ser. 215-233; Ausubel, supra).
  • peptide synthesis can be performed using various solid-phase techniques (Roberge et al. (1995) Science 269:202-204), and machines such as the ABI 431A Peptide synthesizer (PE Biosystems) can be used to automate synthesis.
  • the amino acid sequence may be altered during synthesis and/or combined with sequences from other proteins to produce a variant protein.
  • the invention entails a substantially purified polypeptide comprising the amino acid sequence of SEQ ID NO: 35 and fragments thereof.
  • the polynucleotide sequences can be used in diagnosis, prognosis, treatment, prevention, and selection and evaluation of therapies for atherosclerosis including, but not limited to, stroke, myocardial infarction, hypertension, transient cerebral ischemia, mesenteric ischemia, coronary artery disease, angina pectoris, peripheral vascular disease, intermittent claudication, renal artery stenosis, and hypertension.
  • the polynucleotide sequences may be used to screen a library of molecules for specific binding affinity.
  • the assay can be used to screen a library of DNA molecules, RNA molecules, PNAs, peptides, ribozymes, antibodies, agonists, antagonists, immunoglobulins, inhibitors, proteins including transcription factors, enhancers, repressors, and drugs and the like which regulate the activity of the polynucleotide sequence in the biological system.
  • the assay involves providing a library of molecules, combining the polynucleotide sequence or a fragment thereof with the library of molecules under conditions suitable to allow specific binding, and detecting specific binding to identify at least one molecule which specifically binds the polynucleotide sequence.
  • the polypeptide or a portion thereof may be used to screen libraries of molecules in any of a variety of screening assays.
  • the portion of the polypeptide employed in such screening may be free in solution, affixed to an abiotic or biotic substrate (e.g. borne on a cell surface), or located intracellularly. Specific binding between the polypeptide and molecule may be measured.
  • the assay can be used to screen a library of DNA molecules, RNA molecules, PNAs, peptides, mimetics, ribozymes, antibodies, agonists, antagonists, immunoglobulins, inhibitors, peptides, polypeptides, drugs and the like, which specifically bind the polypeptide.
  • One method for high throughput screening using very small assay volumes and very small amounts of test compound is described in Burbaum et al. U.S. Pat. No. 5,876,946, incorporated herein by reference, which screens large numbers of molecules for enzyme inhibition or receptor binding.
  • the polynucleotide sequences are used for diagnostic purposes to determine the absence, presence, and excess expression of the polypeptide.
  • the polynucleotides may be at least 18 nucleotides long and consist of complementary RNA and DNA molecules, branched nucleic acids, and/or peptide nucleic acids (PNAs).
  • PNAs peptide nucleic acids
  • the polynucleotides are used to detect and quantify gene expression in samples in which expression of NSEQ is correlated with disease.
  • NSEQ can be used to detect genetic polymorphisms associated with a disease. These polymorphisms may be detected in the transcript cDNA.
  • the specificity of the probe is determined by whether it is made from a unique region, a regulatory region, or from a conserved motif. Both probe specificity and the stringency of diagnostic hybridization or amplification (maximal, high, intermediate, or low) will determine whether the probe identifies only naturally occurring, exactly complementary sequences, allelic variants, or related sequences. Probes designed to detect related sequences should preferably have at least 75% sequence identity to any of the polynucleotides encoding PSEQ.
  • Methods for producing hybridization probes include the cloning of nucleic acid sequences into vectors for the production of mRNA probes.
  • Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by adding RNA polymerases and labeled nucleotides.
  • Hybridization probes may incorporate nucleotides labeled by a variety of reporter groups including, but not limited to, radionuclides such as 32 P or 35 S, enzymatic labels such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, fluorescent labels, and the like.
  • the labeled polynucleotide sequences may be used in Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; and in microarrays utilizing samples from subjects to detect altered PSEQ expression.
  • NSEQ can be labeled by standard methods and added to a sample from a subject under conditions for the formation and detection of hybridization complexes. After incubation the sample is washed, and the signal associated with hybrid complex formation is quantitated and compared with a standard value. Standard values are derived from any control sample, typically one that is free of the suspect disease. If the amount of signal in the subject sample is altered in comparison to the standard value, then the presence of altered levels of expression in the sample indicates the presence of the disease. Qualitative and quantitative methods for comparing the hybridization complexes formed in subject samples with previously established standards are well known in the art.
  • Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or to monitor the treatment of an individual subject. Once the presence of disease is established and a treatment protocol is initiated, hybridization or amplification assays can be repeated on a regular basis to determine if the level of expression in the subject begins to approximate that which is observed in a healthy subject. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to many years.
  • the polynucleotides may be used for the diagnosis of a variety of diseases associated with atherosclerosis. These include, but are not limited to, stroke, myocardial infarction, hypertension, transient cerebral ischemia, mesenteric ischemia, coronary artery disease, angina pectoris, peripheral vascular disease, intermittent claudication, renal artery stenosis, and hypertension.
  • the polynucleotides may also be used as targets in a microarray.
  • the microarray can be used to monitor the expression patterns of large numbers of genes simultaneously and to identify splice variants, mutations, and polymorphisms. Information derived from analyses of the expression patterns may be used to determine gene function, to understand the genetic basis of a disease, to diagnose a disease, and to develop and monitor the activities of therapeutic agents used to treat a disease.
  • Microarrays may also be used to detect genetic diversity, single nucleotide polymorphisms which may characterize a particular population, at the genome level.
  • polynucleotides may be used to generate hybridization probes useful in mapping the naturally occurring genomic sequence.
  • Fluorescent in situ hybridization FISH
  • FISH Fluorescent in situ hybridization
  • antibodies or Fabs comprising an antigen binding site that specifically binds PSEQ may be used for the diagnosis of diseases characterized by the over-or-under expression of PSEQ.
  • a variety of protocols for measuring PSEQ including ELISAs, RIAs, and FACS, are well known in the art and provide a basis for diagnosing altered or abnormal levels of expression.
  • Standard values for PSEQ expression are established by combining samples taken from healthy subjects, preferably human, with antibody to PSEQ under conditions for complex formation The amount of complex formation may be quantitated by various methods, preferably by photometric means. Quantities of PSEQ expressed in disease samples are compared with standard values. Deviation between standard and subject values establishes the parameters for diagnosing or monitoring disease.
  • the anti-PSEQ antibodies of the present invention can be used for treatment or monitoring therapeutic treatment for atherosclerosis.
  • the NSEQ, or its complement may be used therapeutically for the purpose of expressing mRNA and polypeptide, or conversely to block transcription or translation of the mRNA.
  • Expression vectors may be constructed using elements from retroviruses, adenoviruses, herpes or vaccinia viruses, or bacterial plasmids, and the like. These vectors may be used for delivery of nucleotide sequences to a particular target organ, tissue, or cell population. Methods well known to those skilled in the art can be used to construct vectors to express nucleic acid sequences or their complements. (See, e.g., Maulik et al.
  • NSEQ may be used for somatic cell or stem cell gene therapy.
  • Vectors may be introduced in vivo, in vitro, and ex vivo.
  • vectors are introduced into stem cells taken from the subject, and the resulting transgenic cells are clonally propagated for autologous transplant back into that same subject.
  • Delivery of NSEQ by transfection, liposome injections, or polycationic amino polymers may be achieved using methods which are well known in the art. (See, e.g., Goldman et al.
  • NSEQ expression may be inactivated using homologous recombination methods which insert an inactive gene sequence into the coding region or other targeted region of NSEQ. (See, e.g. Thomas et al. (1987) Cell 51: 503-512.)
  • Vectors containing NSEQ can be transformed into a cell or tissue to express a missing polypeptide or to replace a nonfunctional polypeptide.
  • a vector constructed to express the complement of NSEQ can be transformed into a cell to downregulate the overexpression of PSEQ.
  • Complementary or antisense sequences may consist of an oligonucleotide derived from the transcription initiation site; nucleotides between about positions ⁇ 10 and +10 from the ATG are preferred.
  • inhibition can be achieved using triple helix base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules.
  • Ribozymes enzymatic RNA molecules, may also be used to catalyze the cleavage of mRNA and decrease the levels of particular mRNAs, such as those comprising the polynucleotide sequences of the invention.
  • Ribozymes may cleave mRNA at specific cleavage sites.
  • ribozymes may cleave mRNAs at locations dictated by flanking regions that form complementary base pairs with the target mRNA. The construction and production of ribozymes is well known in the art and is described in Meyers (supra).
  • RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5′ and/or 3′ ends of the molecule, or the use of phosphorothioate or 2′ O-methyl rather than phosphodiester linkages within the backbone of the molecule.
  • nontraditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases, may be included.
  • an antagonist, or an antibody that binds specifically to PSEQ may be administered to a subject to treat or prevent atherosclerosis.
  • the antagonist, antibody, or fragment may be used directly to inhibit the activity of the polypeptide or indirectly to deliver a therapeutic agent to cells or tissues which express the PSEQ.
  • An immunoconjugate comprising a PSEQ binding site of the antibody or the antagonist and a therapeutic agent may be administered to a subject in need to treat or prevent disease.
  • the therapeutic agent may be a cytotoxic agent selected from a group including, but not limited to, abrin, ricin, doxorubicin, daunorubicin, taxol, ethidium bromide, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, dihydroxy anthracin dione, actinomycin D, diphteria toxin, Pseudomonas exotoxin A and 40, radioisotopes, and glucocorticoid.
  • a cytotoxic agent selected from a group including, but not limited to, abrin, ricin, doxorubicin, daunorubicin, taxol, ethidium bromide, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, dihydroxy anthracin dione, actinomycin D, diphteria toxin, Pseudom
  • Antibodies to PSEQ may be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, and single chain antibodies, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies, such as those which inhibit dimer formation, are especially preferred for therapeutic use. Monoclonal antibodies to PSEQ may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma, the human B-cell hybridoma, and the EBV-hybridoma techniques. In addition, techniques developed for the production of chimeric antibodies can be used.
  • an agonist of PSEQ may be administered to a subject to treat or prevent a disease associated with decreased expression, longevity or activity of PSEQ.
  • An additional aspect of the invention relates to the administration of a pharmaceutical or sterile composition, in conjunction with a pharmaceutically acceptable carrier, for any of the therapeutic applications discussed above.
  • Such pharmaceutical compositions may consist of PSEQ or antibodies, mimetics, agonists, antagonists, or inhibitors of the polypeptide.
  • the compositions may be administered alone or in combination with at least one other agent, such as a stabilizing compound, which may be administered in any sterile, biocompatible pharmaceutical carrier including, but not limited to, saline, buffered saline, dextrose, and water.
  • the compositions may be administered to a subject alone or in combination with other agents, drugs, or hormones.
  • compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.
  • these pharmaceutical compositions may contain pharmaceutically-acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Further details on techniques for formulation and administration may be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing Co., Easton Pa.).
  • the therapeutically effective dose can be estimated initially either in cell culture assays or in animal models such as mice, rats, rabbits, dogs, or pigs.
  • animal models such as mice, rats, rabbits, dogs, or pigs.
  • An animal model may also be used to determine the concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.
  • a therapeutically effective dose refers to that amount of active ingredient which ameliorates the symptoms or condition.
  • Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or with experimental animals, such as by calculating and contrasting the ED 50 (the dose therapeutically effective in 50% of the population) and LD 50 (the dose lethal to 50% of the population) statistics. Any of the therapeutic compositions described above may be applied to any subject in need of such therapy, including, but not limited to, mammals such as dogs, cats, cows, horses, rabbits, monkeys, and most preferably, humans.
  • the cDNA library SMCCNOS01 was selected as an example to demonstrate the construction of cDNA libraries from which the polynucleotides associated with known atherosclerosis-associated genes were derived.
  • the SMCCNOS01 subtracted coronary artery smooth muscle cell library was constructed using 7.56 ⁇ 10 6 clones from the SMCCNOT02 library and was subjected to two rounds of subtraction hybridization for 48 hours with 6.12 ⁇ 10 6 clones from SMCCNOT01.
  • the SMCCNOT02 library was constructed using RNA isolated from coronary artery smooth muscle cells removed from a 3-year-old Caucasian male. The cells were treated for 20 hours with TNF ⁇ and IL-1 ⁇ at 10 ng/ml each.
  • the SMCCNOT01 was constructed using RNA isolated from untreated coronary artery smooth muscle cells from the same donor. Subtractive hybridization conditions were based on the methodologies of Swaroop et al. (1991; Nucleic Acids Res. 19:1954) and Bonaldo et al. (1996; Genome Research 6:791).
  • the mRNA-Oligo(dT) 25 bound streptavidin particles were separated from the supernatant, washed twice with hybridization buffer I (0.1 5 M NaCl, 0.01 M Tris-HCl pH8.0, 1 mM EDTA, 0.1% lauryl sarcosinate) using magnetic separation at each step to remove the supernatant from the particles.
  • hybridization buffer I 0.1 5 M NaCl, 0.01 M Tris-HCl pH8.0, 1 mM EDTA, 0.1% lauryl sarcosinate
  • RNA was used for cDNA synthesis and construction of the cDNA library according to the recommended protocols in the SUPERSCRIPT plasmid system (Life Technologies).
  • the cDNAs were fractionated on a SEPHAROSE CL4B column (Amersham Pharmacia Biotech, Piscataway N.J.), and those cDNAs exceeding 400 bp were ligated into pINCY plasmid (Incyte Pharmaceuticals, Palo Alto, Calif.).
  • Recombinant plasmids were transformed into DH5 ⁇ competent cells or ELECTROMAX cells (Life Technologies).
  • Plasmid DNA was released from the cells and purified using the REAL Prep 96 plasmid kit (Qiagen, Valencia Calif.). The recommended protocol was employed except for the following changes: 1) the bacteria were cultured in 1 ml of sterile Terrific Broth (Life Technologies) with carbenicillin at 25 mg/L and glycerol at 0.4%; 2) after inoculation, the cells were cultured for 19 hours and then lysed with 0.3 ml of lysis buffer; and 3) following isopropanol precipitation, the plasmid DNA pellet was resuspended in 0.1 ml distilled water, and samples were transferred to a 96-well block for storage at 4° C.
  • cDNAs were prepared using a MICROLAB 2200 System (Hamilton, Reno Nev.) in combination with the DNA ENGINE thermal cycler (MJ Research, Watertown Mass.). cDNAs were sequenced by the method of Sanger et al. (1975, J. Mol. Biol. 94:441f) using ABI PRISM 377 (PE Biosystems) or MEGABACE 1000 sequencing systems (Amersham Pharmacia Biotech).
  • sequences used for co-expression analysis were assembled from EST sequences, 5′ and 3′ longread sequences, and full length coding sequences. Selected assembled sequences were expressed in at least three cDNA libraries.
  • Bins were annotated by screening the consensus sequence in each bin against public databases, such as GBpri and GenPept from NCBI.
  • the annotation process involved a FASTn screen against the GBpri database in GenBank. Those hits with a percent identity of greater than or equal to 75% and an alignment length of greater than or equal to 100 base pairs were recorded as homolog hits.
  • the residual unannotated sequences were screened by FASTx against GenPept. Those hits with an E value of less than or equal to 10 ⁇ 8 were recorded as homolog hits.
  • Sequences were then reclustered using BLASTn and Cross-Match, a program for rapid amino acid and nucleic acid sequence comparison and database search (Green, supra), sequentially. Any BLAST alignment between a sequence and a consensus sequence with a score greater than 150 was realigned using cross-match. The sequence was added to the bin whose consensus sequence gave the highest Smith-Waterman score (Smith et al. (1992) Protein Engineering 5:35-51) amongst local alignments with at least 82% identity. Non-matching sequences were moved into new bins, and assembly processes were repeated.
  • Atherosclerosis-associated genes Sixty-six known atherosclerosis-associated genes were selected to identify novel genes that are closely associated with atherosclerosis. The known atherosclerosis-associated genes which were examined in this analysis and brief descriptions of their functions are listed in Table 3. TABLE 3 Descriptions of Known Atherosclerosis-Associated Genes GENE DESCRIPTION AND REFERENCES Human 22kDa Smooth muscle cell-specific gene which is down-regulated during smooth muscle smooth muscle cell dedifferentiation as part of atherogenic process (Sobue et al. (1998) Horm. protein (SM22) Res. 50 Suppl. 2:15-24; Sobue et al. (1999) Mol. Cell. Biochem.
  • Calponin is smooth muscle-specific and may mediate smooth muscle contractility through it's binding of the amino-terminal end of the myosin regulatory light chain.
  • CNN1 calponin
  • Calponin is smooth muscle-specific and may mediate smooth muscle contractility through it's binding of the amino-terminal end of the myosin regulatory light chain.
  • a feature of atherosclerosis Szymanski et al. (1999) Biochemistry 38(12): 3778-84) desmin Contractile component of myofibrils in differentiated smooth muscle cells.
  • DES Regarded as a marker for smooth muscle cells (Shi et al. (1997) Circulation 95(12): 2684-93) smooth muscle Contractile component of myofibrils in differentiated smooth muscle cells.
  • PDGF and (TIMP3) TGFbeta augment TIMP3 expression.
  • Human tissue TIMPs control the activity of matrix metalloproteinases and are important in local inhibitor of matrix remodeling of vasculature.
  • TIMP2 is greatly proteinase-2 increased during neointima formation in organ cultures of human saphenous vein (TIMP-2) (Kranzhofer et al. (1999) Arterioscler. Thromb. Vasc. Biol. 19(2): 255-65)
  • Human tissue TIMPs control the activity of matrix metalloproteinases and are important in local inhibitor of matrix remodeling of vasculature (Greene et al. (1996) J. Biol. Chem. 271(48): metallo- 30375-80) proteinase-4 (TIMP4) pro alpha 1(I) Member of family of fibrous structural proteins. Most abundant structural collagen component of the extracellular matrix.
  • Collagens are important in atherosclerosis for promoting platelet aggregation and for providing sites for platelet adhesion to the vessel wall (Wen et al. (1999) Arterioscler. Thromb. Vasc. Biol.
  • MMP9 localized to lesional macrophages, along with MMP-1, (MMP9) MMP-2, MMP-3.
  • Rabbit aortic macrophage foam cells express immunoreactive MMP-9 (Moreau et al. (1999) Circulation 99(3): 420-426; Zaltsman et al.
  • CSK Cockayne syndrome
  • FGG fibrinogen beta Participant in adhesion and aggregation of platelets which occurs through binding chain gene of platelet receptors.
  • FGG carries the main binding site for the platelet receptor (FGG) binding. Mutations in FGG associated with clotting defects and thrombotic tendency. Fibrin deposition is an integral part of advanced atherosclerotic lesion development (Sueishi et al. (1998) Semin. Thromb. Hemost. 24 (3): 255-60; Cote et al. (1998) Blood 92(7): 2195-2212) pre-pro-von Blood glycoprotein involved in normal hemostasis. Mediates adhesion of platelets Willebrand to sites of vascular damage.
  • VWF blood factor
  • Increased levels of VWF are found in atherosclerosis and in several of its major risk factors, including hypercholesterolemia, diabetes, obesity, hypertension. Levels serve as a predictor of adverse clinical outcome following vascular surgery, possibly as an indicator of thrombus formation (Sadler, J. E. (1998) Annu Rev Biochem 67: 395-424; Blann et al. (1994) Eur. J. Vasc. Surg. 8(1): 10-15; Kessler et al. (1998) Diabetes Metab. 24(4): 327-36; Folsom et al.
  • Circulation 96(4): 1102-1108 coagulation Central role in blood hemostasis by regulating platelet aggregation and blood factor II/ coagulation. Converts fibrinogen to fibrin in the final stage of clotting cascade.
  • prothrombin F2 Promotes cellular chemotaxis and proliferation, extracellular matrix turnover and release of inflammatory cytokines (Goldsack et al. (1998) Int. J. Biochem. Cell. Biol.
  • Deficiency in ATIII causes recurrent venous thrombosis and pulmonary embolism and can be inherited in autosomal dominant fashion (Hultin et al. (1988) Thromb. Haemost. 59(3): 468-73; Lane et al. (1996) Blood Rev. 10(2): 59-74) plasminogen Major physiological inhibitor of fibrinolysis. Plasma levels correlate with activator incidence of MI and venous thrombosis. Both adipocytes and endothelial cells inhibitor-1 produced PAI, possibly under the control of PPARG, as demonstrated using (PAI-1) recombinant PPARG expression constructs in endothelial cell lines. Increased expression of PAI observed in coronary heart disease.
  • APOAII may have ability to convert HDL from an anti- to a pro-inflammatory particle, with paraoxonase having a role in this transformation process.
  • Plasma APOAII levels significantly associated with plasma free fatty acid levels.
  • Transgenic mice expressing varying levels of APOAII show increased atherosclerotic lesions than wt when fed an atherogenic diet. Possible interaction between diet/genotype and atherogenic potential (Escola-Gil et al. (1998) J. Lipid Res. 39(2): 457-462; Warden et al. (1993) Proc. Natl. Acad. Sci.
  • APOB APOB100 underly familial defective apolipoprotein B-100 in which patients suffer from premature atherosclerosis. Mutations result in defect in binding of LDL to LDL receptor, and accumulation of plasma LDL.
  • High-expressing APOB transgenic mice exibit elevated VLDL-LDL cholesterol and atherogenic lesions (Callow et al. (1995) J Clin Invest 96(3): 1639-1646; Brasaemle et al. (1997) J. Biol. Chem.
  • lipoprotein Role in lipoprotein metabolism Cofactor in the activity of lipoprotein lipase the apoCII (APOC2) enzyme that hydrolyzes triglycerides in plasma and transfers the fatty acids to tissues. Mutations in APOC2 responsible for hyperlipoproteinemia 1B. similar to lipoprotein lipase deficiency (Cox et al. (1978) N. Engl. J. Med. 299(26): 1421- 1424; Arimoto et al. (1998) J. Lipid Res.
  • APOC2 apoCII
  • APOC3 triglyceride CIII (APOC3) rich particles.
  • SstI RFLP in apoCIII is associated with plasma triglyceride and apoCIII levels and hyperlipidemic phenotypes (Henderson et al. (1987) Hum. Genet. 75(1): 62-65)
  • apolipoprotein APOC4 is a lipid-binding protein that has the potential to alter lipid metabolism.
  • apoC-IV Human APOC4 transgenic mice are hypertriglyceridaemic compared to normal (APOC4) controls 9Allan et al. (1996) J. Lipid Res. 37(7): 1510-1518) macrophage Mediates binding, internalisation and processing of negatively-charged scavenger macromolecules. Implicated in the pathological deposition of cholesterol in receptor type I arterial walls during atherogenesis (Han et al. (1998) Hum. Mol. Genet. 7(6): (MSR1) 1039-1046) Human antigen Acts as a scavenger receptor for oxidised LDL.
  • carboxyl ester CEL gene expression increases in presence of oxidised and native LDL in vitro. It lipase gene is expressed in the vessel wall and in aortic extracts - may interact with cholesterol (CEL) to modulate progression of atherosclerosis (Li et al. (1998) Biochem. J. 329(Pt 3): 675-679) paraoxonase 1 Serum esterase exclusively associated with high-density lipoproteins; it might (PON1) confer protection against coronary artery disease by destroying pro-inflammatory oxidized lipids in oxidized low-density lipoproteins. PON1 gln192-to-arg polymorphism associated with CAD.
  • HMG CoA coenzyme A reductase is regulated by oxysterols via sterol-regulatory element in the promotor, synthase as is found in APOE.
  • Target for cholesterol-lowering therapies prevastatin, (HMGCR) “statins” (Bocan et al.
  • VLDLR VLDLR
  • perilipin Lipid storage droplets of steroidogenic cells are surrounded by perilipins, family of phosphorylated proteins encoded by a single gene, detected in adipocytes and steroidogenic cells.
  • perilipins family of phosphorylated proteins encoded by a single gene, detected in adipocytes and steroidogenic cells.
  • EDN1 is normally expressed exclusively in endothelial cells.
  • EDN1 expression is enhanced and can be found in the tunica media and vascular smooth muscle cells.
  • Analysis of recombinant EDN1 expression in vitro suggests it influences vascular smooth muscle cell proliferation.
  • Potent vasoconstriction properties (Unoki et al. (1999) Cell Tissue Res. 295(1): 89-99; Rossi et al. (1999) Circulation 99(9): 1147-1155; Yoshizumi et al. (1998) Br. J. Pharmacol.
  • endothelin Mediates action of endothelin1 on vascular smooth muscle migration, proliferation receptor A and monocyte/endothelial cell interaction during initiation and progression of (EDNRA) atherosclerotic lesion development (Kohno et al. (1998) J. Cardiovasc. Pharmacol. 31 Suppl 1: S84-9; Alberts et al. (1994) J. Biol Chem 269(13): 10112-10118) interleukin 6 Inflammatory cytokine present in arterial atherosclerotic wall which is upregulated (IL6) by platelets to stimulate smooth muscle cell growth.
  • IL6 interleukin 6 Inflammatory cytokine present in arterial atherosclerotic wall which is upregulated
  • IL6 Increased expression of IL6 in atherosclerotic aortas of APOE knockout vs aortas from aged-matched controls.
  • Secretion levels of IL6 is positively associated with increased lesion surface area in APOE aortic tissue samples (Sukovich, et al. (1998) Arterioscler. Thromb. Vasc. Biol. 18(9): 1498-1505; Loppnow, et al. (1998) Blood 91(1): 134-141)
  • interleukin 1 May contribute to regulation of local pathogenesis in the vessel wall by activation (IL1) of the cytokine regulatory network.
  • IL-1 antagonist inhibits platelet-induced cytokine production of smooth muscle cells (Loppnow et al.
  • PSGDS Northern analysis shows strong specific expression in heart. Immunocytochemical localisation to myocardial and atrio endocardial cells, and accumulates in end-stage atherosclerotic plaques. High plasma levels detected in severe angina patients (Eguchi et al. (1997) Proc. Natl. Acad. Sci. USA 94(26): 14689-14694) Annexin Inhibits phospholipase A2 activity and hence the production of arachidonic acid, II/lipocortinII the precursor of the inflammatory mediators prostaglandins and leukotrienes. (ANX2) ANX2 is an important anti-inflammatory molecule.
  • ANX1 ANXI is an important anti-inflammatory molecule (Wallner, et al.
  • Prostaglandin- Major mechanism for the regulation of prostaglandin synthesis Arachidonic acid endoperoxide pathway. Role in inflammation and endothelial cell migration/angiogenesis. Synthase 2 Regulated enzyme - major mediator of inflammation. Antiinflammatory (PTGS2) glucocorticoids are potent inhibitors of this cyclooxygenase. Over expression of PTGS2 in vitro in rabbit epithelial cells causes increased adhesion to extracellular matrix proteins and inhibition of apoptosis, hallmarks of atherosclerotic plaque formation (Morham et al. (1995) Cell 83(3): 473-482; O'Banion et al.
  • IGFBP1 insulin-like protein-1 IGF1/IGFBP1 system found to be associated with cardiovascular risk and (IGFBP-1) atherosclerosis (Janssen et al. (1998) Arterioscler. Thromb. Vasc. Biol. 18(2): 277-282) Secreted protein, Extracellular glycoprotein secreted by endothelial cells which has a suspected role acidic and rich in in calcification of atherosclerotic plaques.
  • SPARC SPARC
  • PDGF-B cysteine dimers
  • Expression of SPARC and PDGF is (SPARC) minimal in most adult tissues, but is enhanced following injury and advanced atherosclerotic lesions.
  • SPARC selective expression of SPARC causes rounding of adherent endothelial cells and influences extravasation of macromolecules (Raines et al. (1992) Proc. Natl. Acad Sci U.S.A. 89(4): 1281-1285; Goldblum et al. (1994) Proc. Natl. Acad. Sci.
  • NF- Activated NF kappa B occurs in atherosclerotic lesions, and regulates the kappa-B expression of gene important in recruitment of monocytes and inflammatory transcription response.
  • NFkB smooth muscle cells during factor
  • AAS renin-angiotensin system
  • AGT Hypertensive mice carrying renin and angiotensinogen transgenes found to have higher total cholesterol levels on an atherogenic diet than their wt counterparts, and atherogenic lesions were 4 ⁇ larger in surface area. Suggests hypertension induced by activated RAS is important atherogenic factor (Sugiyama et al. (1997) Lab. Invest. 76(6): 835-842) Nitric Oxide Mediates basal vasodilation.
  • NOS3 reactive oxygen
  • Nitric Oxide Mediates basal vasodilation. Regulates the production of nitric oxide, an Synthase 2 important signal transduction component and scavenger of reactive oxygen (NOS2) species. NOS2, known as inducible NOS is expressed in most cells only after induction by immunologic and inflammatory stimuli, and is upregulated in pathological conditions such as atherosclerosis (Dusting et al. (1998) Clin. Expt. Pharmacol. Phisiol. Suppl. 25: S34-41)
  • novel atherosclerosis-associated polynucleotides identified are listed in the table by their SEQ ID NOs numbers, and the known genes, by their names or the abbreviations shown in Table 3. TABLE 4 Co-expression of 34 novel genes with 66 known atherosclerosis genes.
  • Polynucleotides comprising the consensus sequences of SEQ ID NO: 1-34 of the present invention were first identified from Incyte bins and assembled as described in Example III. BLAST and other motif searches were performed for SEQ ID NOs: 1-34 according to Example VI. The full length and 5′-complete sequences were translated and sequence identity was sought with known sequences.
  • SEQ ID NO: 35 of the present invention was encoded by the nucleic acids of SEQ ID NO: 11.
  • SEQ ID NO: 35 has 366 amino acids which are encoded by SEQ ID NO: 11.
  • Motif analyses of SEQ ID NO: 35 shows one potential cAMP- and cGMP-dependent protein kinase phosphorylation sites at residue S343, two potential casein kinase II phosphorylation sites at residues S179 and T351, and four potential protein kinase C phosphorylation sites at residues T29, S85, T269, and T324. Additionally, SEQ ID NO: 35 contains a potential sugar transport protein signature sequence from residues L201 to S217.
  • polypeptide sequence SEQ ID NO: 35
  • databases derived from sources such as GenBank and SwissProt. These databases, which contain previously identified and annotated sequences, were searched for regions of similarity using BLAST (Altschul, supra). BLAST searched for matches and reported only those that satisfied the probability thresholds of 10 ⁇ 25 or less for nucleotide sequences and 10 ⁇ 8 or less for polypeptide sequences.
  • the polypeptide sequence was also analyzed for known motif patterns using MOTIFS, SPSCAN, BLIMPS, and HMM-based protocols.
  • MOTIFS Genetics Computer Group, Madison Wis.
  • SPSCAN Genetics Computer Group searches polypeptide sequences for patterns that match those defined in the Prosite Dictionary of Protein Sites and Patterns (Bairoch, supra) and displays the patterns found and their corresponding literature abstracts.
  • SPSCAN Genetics Computer Group searches for potential signal peptide sequences using a weighted matrix method (Nielsen et al. (1997) Prot. Eng. 10: 1-6). Hits with a score of 5 or greater were considered.
  • BLIMPS uses a weighted matrix analysis algorithm to search for sequence similarity between the polypeptide sequences and those contained in BLOCKS, a database consisting of short amino acid segments, or blocks of 3-60 amino acids in length, compiled from the PROSITE database (Henikoff; supra; Bairoch, supra), and those in PRINTS, a protein fingerprint database based on non-redundant sequences obtained from sources such as SwissProt, GenBank, PIR, and NRL-3D (Attwood et al. (1997) J. Chem. Inf. Comput. Sci. 37:417-424).
  • the BLIMPS searches reported matches with a cutoff score of 1000 or greater and a cutoff probability value of 1.0 ⁇ 10 ⁇ 3 .
  • HMM-based protocols were based on a probabilistic approach and searched for consensus primary structures of gene families in the protein sequences (Eddy, supra; Sonnhammer, supra). More than 500 known protein families with cutoff scores ranging from 10 to 50 bits were selected for use in this invention.
  • Nucleic acids are isolated from a biological source and applied to a substrate for standard hybridization protocols by one of the following methods.
  • a mixture of target nucleic acids, a restriction digest of genomic DNA is fractionated by electrophoresis through an 0.7% agarose gel in 1xTAE [Tris-acetate-ethylenediamine tetraacetic acid (EDTA)] running buffer and transferred to a nylon membrane by capillary transfer using 20x saline sodium citrate (SSC).
  • the target nucleic acids are individually ligated to a vector and inserted into bacterial host cells to form a library.
  • Target nucleic acids are arranged on a substrate by one of the following methods.
  • bacterial cells containing individual clones are robotically picked and arranged on a nylon membrane.
  • the membrane is placed on bacterial growth medium, LB agar containing carbenicillin, and incubated at 37° C. for 16 hours.
  • Bacterial colonies are denatured, neutralized, and digested with proteinase K.
  • Nylon membranes are exposed to UV irradiation in a STRATALINKER UV-crosslinker (Stratagene) to cross-link DNA to the membrane.
  • target nucleic acids are amplified from bacterial vectors by thirty cycles of PCR using primers complementary to vector sequences flanking the insert.
  • Amplified target nucleic acids are purified using SEPHACRYL-400 beads (Amersham Pharnacia Biotech).
  • Purified target nucleic acids are robotically arrayed onto a glass microscope slide (Corning Science Products, Corning N.Y.). The slide is previously coated with 0.05% aminopropyl silane (Sigma-Aldrich, St. Louis Mo.) and cured at 110° C.
  • the arrayed glass slide (microarray) is exposed to UV irradiation in a STRATALINKER UV-crosslinker (Stratagene).
  • cDNA probes are made from mRNA templates. Five micrograms of mRNA is mixed with 1 ⁇ g random primer (Life Technologies), incubated at 70° C. for 10 minutes, and lyophilized. The lyophilized sample is resuspended in 50 ⁇ l of 1x first strand buffer (cDNA Synthesis systems; Life Technologies) containing a dNTP mix, [ ⁇ - 32 P]dCTP, dithiothreitol, and MMLV reverse transcriptase (Stratagene), and incubated at 42° C. for 1-2 hours. After incubation, the probe is diluted with 42 ⁇ l dH 2 O, heated to 95° C. for 3 minutes, and cooled on ice.
  • cDNA Synthesis systems Life Technologies
  • mRNA in the probe is removed by alkaline degradation.
  • the probe is neutralized, and degraded mRNA and unincorporated nucleotides are removed using a PROBEQUANT G-50 microcolumn (Amersham Pharmacia Biotech).
  • Probes can be labeled with fluorescent markers, Cy3-dCTP or Cy5-dCTP (Amersharn Pharmacia Biotech), in place of the radionucleotide, [ 32 P]dCTP.
  • Hybridization is carried out at 65° C. in a hybridization buffer containing 0.5 M sodium phosphate (pH 7.2), 7% SDS, and 1 mM EDTA. After the substrate is incubated in hybridization buffer at 65° C. for at least 2 hours, the buffer is replaced with 10 ml of fresh buffer containing the probes. After incubation at 65° C. for 18 hours, the hybridization buffer is removed, and the substrate is washed sequentially under increasingly stringent conditions, up to 40 mM sodium phosphate, 1% SDS, 1 mM EDTA at 65° C.
  • the substrate is exposed to a PHOSPHORIMAGER cassette (Amersham Pharmacia Biotech), and the image is analyzed using IMAGEQUANT data analysis software (Amersham Pharmacia Biotech).
  • a fluorescent probe hybridized on a microarray the substrate is examined by confocal laser microscopy, and images are collected and analyzed using GEMTOOLS gene expression analysis software (Incyte Pharmaceuticals).
  • Molecules complementary to the polynucleotide, or a fragment thereof are used to detect, decrease, or inhibit gene expression.
  • oligonucleotides comprising from about 18 to about 60 base pairs is described, the same procedure is used with larger or smaller fragments or their derivatives (PNAs).
  • Oligonucleotides are designed using OLIGO 4.06 software (National Biosciences) and SEQ ID NO: 1-34 or fragments thereof
  • a complementary oligonucleotide is designed to bind to the most unique 5′ sequence, most preferably about 10 nucleotides before the initiation codon of the open reading frame.
  • a complementary oligonucleotide is designed to prevent ribosomal binding to the mRNA encoding the polypeptide.
  • polypeptides encoded by SEQ ID NO: 1-34, or portions thereof, substantially purified using polyacrylamide gel electrophoresis or other purification techniques, is used to immunize rabbits and to produce antibodies using standard protocols as described in Pound (1998; Immunochemical Protocols, Methods Mol. Biol. Vol. 80).
  • amino acid sequence is analyzed using LASERGENE software (DNASTAR, Madison Wis.) to determine regions of high immunogenicity, and a corresponding oligopeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Methods for selection of epitopes, such as those near the C-terminus or in hydrophilic regions are well described in the art.
  • oligopeptides 15 residues in length are synthesized using an ABI431A Peptide synthesizer (PE Biosystems) using fmoc-chemistry and coupled to keyhole limpet hemocyanin (KLH, Sigma-Aldrich) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (Ausubel, supra) to increase immunogenicity.
  • Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. Resulting antisera are tested for antipeptide activity by, for example, binding the peptide to plastic, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio-iodinated goat anti-rabbit IgG.
  • polynucleotide, or fragments thereof, or the polypeptide, or portions thereof are labeled with 32 P-dCTP, Cy3-dCTP, or Cy5-dCTP (Amersham Pharmacia Biotech), or with BIODIPY or FITC (Molecular Probes, Eugene OR), respectively.
  • Libraries of candidate molecules previously arranged on a substrate are incubated in the presence of labeled polynucleotide or polypeptide. After incubation under conditions for either a nucleic acid or amino acid sequence, the substrate is washed, and any position on the substrate retaining label, which indicates specific binding or complex formation, is assayed, and the binding molecule is identified. Data obtained using different concentrations of the polynucleotide or polypeptide are used to calculate affinity between the labeled nucleic acid or protein and the bound molecule.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
US09/349,015 1999-01-20 1999-07-07 Atherosclerosis-associated genes Abandoned US20020015950A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
US09/349,015 US20020015950A1 (en) 1999-07-07 1999-07-07 Atherosclerosis-associated genes
AU58988/00A AU5898800A (en) 1999-07-07 2000-06-28 Atherosclerosis-associated genes
EP00944981A EP1196564A2 (fr) 1999-07-07 2000-06-28 Genes associes a l'atherosclerose
JP2001509468A JP2003504044A (ja) 1999-07-07 2000-06-28 アテローム性動脈硬化に関連する遺伝子
CA002378985A CA2378985A1 (fr) 1999-07-07 2000-06-28 Genes associes a l'atherosclerose
PCT/US2000/017887 WO2001004264A2 (fr) 1999-07-07 2000-06-28 Genes associes a l'atherosclerose
US09/642,703 US6524799B1 (en) 1999-07-07 2000-08-16 DNA encoding sparc-related proteins
US10/219,664 US20030129176A1 (en) 1999-07-07 2002-08-14 Atherosclerosis-associated genes
US10/247,451 US20040018188A9 (en) 1999-01-20 2002-09-18 Sparc-related proteins

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/349,015 US20020015950A1 (en) 1999-07-07 1999-07-07 Atherosclerosis-associated genes

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/840,787 Continuation-In-Part US20020058264A1 (en) 1997-09-23 2001-09-26 Human regulatory molecules

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US09/642,703 Continuation-In-Part US6524799B1 (en) 1999-01-20 2000-08-16 DNA encoding sparc-related proteins
US10/219,664 Continuation-In-Part US20030129176A1 (en) 1999-07-07 2002-08-14 Atherosclerosis-associated genes
US10/247,451 Continuation-In-Part US20040018188A9 (en) 1999-01-20 2002-09-18 Sparc-related proteins

Publications (1)

Publication Number Publication Date
US20020015950A1 true US20020015950A1 (en) 2002-02-07

Family

ID=23370530

Family Applications (3)

Application Number Title Priority Date Filing Date
US09/349,015 Abandoned US20020015950A1 (en) 1999-01-20 1999-07-07 Atherosclerosis-associated genes
US09/642,703 Expired - Fee Related US6524799B1 (en) 1999-01-20 2000-08-16 DNA encoding sparc-related proteins
US10/219,664 Abandoned US20030129176A1 (en) 1999-07-07 2002-08-14 Atherosclerosis-associated genes

Family Applications After (2)

Application Number Title Priority Date Filing Date
US09/642,703 Expired - Fee Related US6524799B1 (en) 1999-01-20 2000-08-16 DNA encoding sparc-related proteins
US10/219,664 Abandoned US20030129176A1 (en) 1999-07-07 2002-08-14 Atherosclerosis-associated genes

Country Status (6)

Country Link
US (3) US20020015950A1 (fr)
EP (1) EP1196564A2 (fr)
JP (1) JP2003504044A (fr)
AU (1) AU5898800A (fr)
CA (1) CA2378985A1 (fr)
WO (1) WO2001004264A2 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030113327A1 (en) * 2001-05-25 2003-06-19 Adams Sean H. Compositions and methods for adipose abundant protein
US20030175860A1 (en) * 2000-12-18 2003-09-18 Sheppard Paul O. Seleno-cysteine containing protein zsel1
US20070218513A1 (en) * 2003-10-16 2007-09-20 Novartis Ag Differentially Expressed Genes Related to Coronary Artery Disease
US20100316622A1 (en) * 2007-11-02 2010-12-16 University Of Miami Diagnosis and treatment of cardiac disorders
US8663122B2 (en) 2005-01-26 2014-03-04 Stuart Schecter LLC Cardiovascular haptic handle system
US8942828B1 (en) 2011-04-13 2015-01-27 Stuart Schecter, LLC Minimally invasive cardiovascular support system with true haptic coupling
US10013082B2 (en) 2012-06-05 2018-07-03 Stuart Schecter, LLC Operating system with haptic interface for minimally invasive, hand-held surgical instrument
CN111458512A (zh) * 2019-01-21 2020-07-28 中国科学院分子细胞科学卓越创新中心 一种动脉粥样硬化生物标志物及其用途
US12104210B2 (en) 2016-09-01 2024-10-01 The George Washington University Blood RNA biomarkers of coronary artery disease

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8609614B2 (en) * 1998-07-22 2013-12-17 Vanderbilt University GBS toxin receptor compositions and methods of use
DE60043784D1 (de) * 1999-12-06 2010-03-18 Agensys Inc Serpentinetransmembranrezeptoren exprimiert in menschlichem prostatakrebs und ihre verwendungen
CN1433482A (zh) * 1999-12-09 2003-07-30 三共株式会社 高脂血症的治疗或预防剂的检验方法
WO2001066738A2 (fr) * 2000-03-06 2001-09-13 Eli Lilly And Company Acides nucleiques codant des polypeptides crsp1 humains et utilisations de ces derniers
EP2123293A3 (fr) * 2000-12-14 2010-09-08 Amylin Pharmaceuticals, Inc. Peptide YY et agonistes du peptide YY pour le traitement de troubles métaboliques
US20030113728A1 (en) * 2001-12-14 2003-06-19 Jukka Salonen Method for assessing the risk of cardiovascular disease
JP2006512924A (ja) * 2002-08-15 2006-04-20 ジェンザイム・コーポレーション 脳内皮細胞発現パターン
GB0408685D0 (en) * 2004-04-19 2004-05-19 Guys & St Thomas Hospital Trus Diagnostic method
AU2006249235B2 (en) 2004-05-14 2010-11-11 Abraxis Bioscience, Llc Sparc and methods of use thereof
US8697139B2 (en) 2004-09-21 2014-04-15 Frank M. Phillips Method of intervertebral disc treatment using articular chondrocyte cells
CA2958259C (fr) 2004-10-22 2020-06-30 Revivicor, Inc. Ongules dotes de systemes immunitaires a modification genetique
US7553496B2 (en) * 2004-12-21 2009-06-30 University Of Kentucky Research Foundation VEGF-A as an inhibitor of angiogenesis and methods of using same
WO2006078776A2 (fr) * 2005-01-19 2006-07-27 The Trustees Of The University Of Pennsylvania Inhibiteurs et procedes de traitement de maladies cardio-vasculaires, et procede pour l'identification d'inhibiteurs
WO2006112930A2 (fr) * 2005-02-18 2006-10-26 Abraxis Bioscience, Inc. Sparc mutant a deletion q3 et utilisations dudit polypeptide mutant
WO2006102497A2 (fr) * 2005-03-22 2006-09-28 The Board Of Trustees Of The Leland Stanford Junior University Procedes et compositions de diagnostic, surveillance et developpement de medicaments destines au traitement de l'atherosclerose
US8586534B2 (en) * 2007-05-08 2013-11-19 Albert Einstein College Of Medicine Of Yeshiva University Intracellular domain of a mammalian Fat1 (Fat1IC)
WO2009148050A1 (fr) * 2008-06-04 2009-12-10 株式会社バイオマーカーサイエンス Procédé d’évaluation des effets d’atténuation et de prévention de l’artériosclérose, kit pour l’évaluation et procédé de criblage de substance
US20110256100A1 (en) * 2008-08-06 2011-10-20 Katholieke Universiteit Leuven Secreted modular calcium binding protein for intracellular modulation of bone morphogenetic protein signaling
WO2010051288A1 (fr) 2008-10-27 2010-05-06 Revivicor, Inc. Ongulés immunodéprimés
JP2010190804A (ja) * 2009-02-19 2010-09-02 Biomarker Science:Kk 動脈硬化改善・予防効果の評価方法及び評価用キット、並びに、物質のスクリーニング方法
WO2011027132A1 (fr) 2009-09-03 2011-03-10 Cancer Research Technology Limited Inhibiteurs de clec14a
US20130004519A1 (en) * 2010-03-05 2013-01-03 Ruth Chiquet-Ehrismann Smoci, tenascin-c and brain cancers
WO2017141980A1 (fr) * 2016-02-16 2017-08-24 公立大学法人横浜市立大学 Biomarqueur sanguin de détection d'artériosclérose
US11074433B2 (en) * 2016-12-12 2021-07-27 Nec Corporation Information processing apparatus, genetic information generation method and program
ES2688737A1 (es) * 2017-05-04 2018-11-06 Universidad Del País Vasco / Euskal Herriko Unibertsitatea Método para diagnosticar placa ateroesclerótica inestable

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0976824A1 (fr) * 1998-07-10 2000-02-02 Amsterdam Molecular Therapeutics Gène et protéine impliqué dans la régénération du foie

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030175860A1 (en) * 2000-12-18 2003-09-18 Sheppard Paul O. Seleno-cysteine containing protein zsel1
US20030113327A1 (en) * 2001-05-25 2003-06-19 Adams Sean H. Compositions and methods for adipose abundant protein
WO2002096355A3 (fr) * 2001-05-25 2005-11-17 Genentech Inc Compositions et procedes pour proteine d'adipose abondante
US20070218513A1 (en) * 2003-10-16 2007-09-20 Novartis Ag Differentially Expressed Genes Related to Coronary Artery Disease
US8663122B2 (en) 2005-01-26 2014-03-04 Stuart Schecter LLC Cardiovascular haptic handle system
US8956304B2 (en) 2005-01-26 2015-02-17 Stuart Schecter LLC Cardiovascular haptic handle system
US20100316622A1 (en) * 2007-11-02 2010-12-16 University Of Miami Diagnosis and treatment of cardiac disorders
US8942828B1 (en) 2011-04-13 2015-01-27 Stuart Schecter, LLC Minimally invasive cardiovascular support system with true haptic coupling
US10013082B2 (en) 2012-06-05 2018-07-03 Stuart Schecter, LLC Operating system with haptic interface for minimally invasive, hand-held surgical instrument
US12104210B2 (en) 2016-09-01 2024-10-01 The George Washington University Blood RNA biomarkers of coronary artery disease
CN111458512A (zh) * 2019-01-21 2020-07-28 中国科学院分子细胞科学卓越创新中心 一种动脉粥样硬化生物标志物及其用途

Also Published As

Publication number Publication date
US6524799B1 (en) 2003-02-25
CA2378985A1 (fr) 2001-01-18
EP1196564A2 (fr) 2002-04-17
US20030129176A1 (en) 2003-07-10
WO2001004264A2 (fr) 2001-01-18
JP2003504044A (ja) 2003-02-04
AU5898800A (en) 2001-01-30
WO2001004264A3 (fr) 2001-07-26

Similar Documents

Publication Publication Date Title
US20020015950A1 (en) Atherosclerosis-associated genes
US6566325B2 (en) 49 human secreted proteins
ES2397441T3 (es) Secuencias polinucleotídicas y polipeptídicas implicadas en el proceso de remodelación ósea
US20020102569A1 (en) Diagnostic marker for cancers
US20080051338A1 (en) 98 Human Secreted Proteins
WO2002072596A1 (fr) Proteine associee a la steap
US20040248256A1 (en) Secreted proteins and polynucleotides encoding them
CA2364541A1 (fr) Genes associes aux maladies du rein
US20020076705A1 (en) 31 human secreted proteins
US20040152164A1 (en) 62 human secreted proteins
US6225451B1 (en) Chromosome 11-linked coronary heart disease susceptibility gene CHD1
CA2518101A1 (fr) Compositions et procedes permettant de traiter un lupus erythemateux systemique
US20030186333A1 (en) Down syndrome critical region 1-like protein
US20020019000A1 (en) Polynucleotides coexpressed with matrix-remodeling genes
US20050037454A1 (en) Gene associated with bone disorders
US20040225118A1 (en) 31 human secreted proteins
US20030054446A1 (en) Novel retina-specific human proteins C7orf9, C12orf7, MPP4 and F379
CA2413158A1 (fr) Marqueur tumoral associe a la matrice extracellulaire
JP2004505637A (ja) ガン関連ｓｉｍ２遺伝子
US20030170627A1 (en) cDNAs co-expressed with placental steroid synthesis genes
US20030129655A1 (en) Nucleic acids encoding GTPase activating proteins
AU2002328200B2 (en) DNA sequences for human angiogenesis genes
JP2003520031A (ja) ２８個のヒト分泌タンパク質
US6444443B1 (en) Gene
EP1538161A2 (fr) 32 protéines secretées humaines

Legal Events

Date Code Title Description
AS Assignment

Owner name: INCYTE PHARMACEUTICALS, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:JONES, KAREN ANN;VOLKMUTH, WAYNE;WALKER, MICHAEL G.;REEL/FRAME:010308/0237;SIGNING DATES FROM 19990702 TO 19990907

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION